The FDA cleared FebriDx to be marketed by healthcare providers in urgent care and emergency care settings, the Australian-based company said in a July 3 news release. It’s meant to aid clinicians in diagnosing acute bacterial respiratory infections.
Lumos officials said the test can play an important role in antibiotic stewardship by aiding clinicians in differentiating between bacterial and viral-associated respiratory illness.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.